Russia's endowment of drugs included in the new who recommendations on tuberculosis therapy. Part 1. Production of drugs on the territory of Russia

The report presents the results of an analytical study of the industrial provision of Russia with antibiotics in accordance with the new WHO recommendations for the treatment of tuberculosis. The analysis of Russian manufacturers of active pharmaceutical ingredient (API) and dosage form (DF) of anti-tuberculosis drugs was carried out. A conclusion was made about the relative vulnerability of the healthcare system of the Russian Federation in relation to the treatment of tuberculosis: out of 22 types of antibiotics 5 are produced only from imported API, 13 are produced from imported and domestic API (quasi-import), 2 types are not produced in the Russian Federation, but are allowed for import, 2 types are not registered in the Russian Federation. In the production of 13 types of antibiotics, the share of API suppliers from Russia does not exceed 27%. The share of foreign API suppliers in the production of pharmaceutical products in Russia is as follows: India (5–100%), China (3–81%), Israel (4%), Republic of Korea (7–63.5%), Taiwan (3%), Thailand (20-40%), EU (3-100%). Maps showing the main territorial clusters of drug manufacturers and API suppliers are presented. The logistical risks and logistical connections of the participants in the production of drugs are described.